Principal Investigator
Matt Fisher, MD qualified from Bristol Medical School in 2015 and worked as a doctor in general and emergency medicine for five years in the NHS. During this period, he also completed a Graduate Diploma in Law and was an NHS Innovation Fellow. Dr Fisher started in clinical development roughly four years ago and has worked for both a CRO and a Sponsor. He has led clinical trials in ATTR Amyloidosis from Phase 1-3 for CROs and was involved with regulatory submissions, protocol development, and early stage clinical development strategy at Sponsor level.
